Aybintio (bevacizumab biosimilar) / Samsung, 3SBio, Mundipharma - LARVOL DELTA

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2 | N=169 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Jan 2025

Trial completion • Trial completion date • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • BRAF

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial (clinicaltrials.gov) - P3 | N=129 | Not yet recruiting | Sponsor: City of Hope Medical Center

New P3 trial • Appendix Cancer • Colorectal Cancer • Oncology • Solid Tumor

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Brain Cancer • Endometrial Adenocarcinoma • Endometrial Cancer • Endometrial Serous Adenocarcinoma • Fallopian Tube Cancer • Glioblastoma • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • Uterine Cancer • BRAF

Texas' Abortion Ban Conflicts With Person-Centered Health Care: Experiences of Texans With Medically Complex Pregnancies. (PubMed, Womens Health Issues) - "Pregnant Texans with medically complex conditions described major gaps in quality of care after SB8. Where abortion care cannot be provided by law, health systems can better meet patients' needs by providing effective transitions of care."

Journal

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (clinicaltrials.gov) - P3 | N=255 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P3 trial • pMMR • Endometrial Cancer • Oncology • Solid Tumor

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (clinicaltrials.gov) - P1/2 | N=280 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | N=78 ➔ 280

Enrollment change • Platinum resistant • Platinum sensitive • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: National Cancer Institute (NCI) | Initiation date: Jan 2026 ➔ Jun 2025

Trial initiation date • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor

A092001: Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Aug 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Mesothelioma • Oncology • Peritoneal Mesothelioma • Psoriatic Arthritis • Solid Tumor

NCI-2018-01503: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P2 | N=96 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Platinum resistant • Trial completion date • Trial primary completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Solid Tumor • MSLN

ZIABC011078: Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma (clinicaltrials.gov) - P2 | N=63 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: Oct 2025 ➔ Oct 2026

IO biomarker • Trial completion date • Trial primary completion date • Alveolar Soft Tissue Sarcoma • Oncology • Sarcoma • Solid Tumor

Preferred strategies for obtaining abortion care among pregnant Texans: a latent class analysis. (PubMed, Contraception) - "Most Texans seeking abortion were interested in a variety of in-person and virtual strategies for obtaining abortion if they could not do so in Texas. Information about the safety and legality of options for abortion care and about financial and logistical-support resources could improve accessibility for those facing greater constraints."

Journal

CALGB 40603: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - P2 | N=454 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Feb 2026 ➔ Sep 2025

Trial completion • Trial completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

Maternal Morbidity following Periviable Prelabor Rupture of Membranes after Texas Senate Bill 8. (PubMed, Am J Perinatol) - "Standard practice prior to Texas Senate Bill 8 (SB8) for those with periviable prelabor rupture of membranes (PROM) without contraindications to expectant management was to offer termination of pregnancy or expectant management...These results provide evidence that periviable PROM alone is a life-threatening condition with serious risk of maternal harm. Waiting for maternal infection or hemorrhage to develop before offering pregnancy termination increases risks of serious maternal morbidity."

Journal • Critical care • Hematological Disorders • Infectious Disease • Postpartum Hemorrhage • Septic Shock

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - P1/2 | N=85 | Recruiting | Sponsor: Mayo Clinic | N=54 ➔ 85

Checkpoint inhibition • Enrollment change • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer (clinicaltrials.gov) - P1/2 | N=35 | Recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Cervical Adenocarcinoma • Cervical Cancer • Cervical Squamous Cell Carcinoma • Oncology • Solid Tumor • Squamous Cell Carcinoma

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (clinicaltrials.gov) - P3 | N=120 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Active, not recruiting

dMMR • Enrollment closed • Mismatch repair • MSI-H • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Microsatellite Instability • Oncology • Rectal Cancer • Solid Tumor • MLH1 • MSH2 • MSH6 • MSI

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov) - P2 | N=88 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Psoriatic Arthritis • Solid Tumor • IL2

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial (clinicaltrials.gov) - P3 | N=252 | Not yet recruiting | Sponsor: NRG Oncology

New P3 trial • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Increase in Healthcare Utilization of Texas Infants with Congenital Anomalies Following Senate Bill 8. (PubMed, J Pediatr) - "Following SB8, inpatient admissions and charges for infants with congenital anomalies increased significantly. Although these patients represent a small proportion of admissions, their care accounts for a disproportionate share of hospital costs and increased by $1.89 billion following SB8. Future studies should explore outpatient costs and long-term outcomes following abortion restrictions."

HEOR • Journal

Blood Transfusions for Pregnancy Loss in Texas Before and After Abortion Bans, 2017‒2023. (PubMed, Am J Public Health) - "To measure changes in blood transfusion related to pregnancy loss in Texas after the 2021 Senate Bill 8 (SB8), which banned abortion after the detection of fetal cardiac activity (6-week ban), and the ban that was enforced after the 2022 Dobbs v Jackson Supreme Court decision, which banned abortion at all gestational durations (total ban)...Published online ahead of print September 11, 2025:e1-e8. https://doi.org/10.2105/AJPH.2025.308224)."

Journal

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (clinicaltrials.gov) - P3 | N=692 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2025 ➔ Jul 2026

Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (clinicaltrials.gov) - P2 | N=7 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | N=112 ➔ 7 | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2025 ➔ Feb 2025

Enrollment change • Trial completion date • Trial primary completion date • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Novel Halotolerant Bacteria from Saline Environments: Isolation and Biomolecule Production. (PubMed, BioTech (Basel)) - "Based on their phenotypic and molecular characteristics, the four halotolerant bacteria were identified as Halomonas elongata SB8, Bacillus altitudinis CN6, Planococcus rifietoensis CN8, and Halomonas stenophila IB5...rifietoensis CN8 produced the highest carotenoid concentration with antifungal and antimicrobial activity. Exploring these organisms opens new pathways for bioremediation, industrial bioprocessing, and sustainable biomolecule production."

Journal

The Impact of State Legislation on the Incidence of Births With Congenital Anomalies in Texas. (PubMed, Ann Surg) - "With the passage of SB8, the incidence of births with congenital anomalies increased substantially in Texas. Further research is warranted on the long-term implications of this increase."

Journal